189 related articles for article (PubMed ID: 38486128)
1. NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.
Bonato A; Chakraborty S; Bomben R; Canarutto G; Felician G; Martines C; Zucchetto A; Pozzo F; Vujovikj M; Polesel J; Chiarenza A; Del Principe MI; Del Poeta G; D'Arena G; Marasca R; Tafuri A; Laurenti L; Piazza S; Dimovski AJ; Gattei V; Efremov DG
Leukemia; 2024 Mar; ():. PubMed ID: 38486128
[TBL] [Abstract][Full Text] [Related]
2. IκBε deficiency accelerates disease development in chronic lymphocytic leukemia.
Bordini J; Lenzi C; Frenquelli M; Morabito A; Pseftogas A; Belloni D; Mansouri L; Tsiolas G; Perotta E; Ranghetti P; Gandini F; Genova F; Hägerstrand D; Gavriilidis G; Keisaris S; Pechlivanis N; Davi F; Kay NE; Langerak AW; Pospisilova S; Scarfò L; Makris A; Psomopoulos FE; Stamatopoulos K; Rosenquist R; Campanella A; Ghia P
Leukemia; 2024 Jun; 38(6):1287-1298. PubMed ID: 38575671
[TBL] [Abstract][Full Text] [Related]
3. Functional loss of IκBε leads to NF-κB deregulation in aggressive chronic lymphocytic leukemia.
Mansouri L; Sutton LA; Ljungström V; Bondza S; Arngården L; Bhoi S; Larsson J; Cortese D; Kalushkova A; Plevova K; Young E; Gunnarsson R; Falk-Sörqvist E; Lönn P; Muggen AF; Yan XJ; Sander B; Enblad G; Smedby KE; Juliusson G; Belessi C; Rung J; Chiorazzi N; Strefford JC; Langerak AW; Pospisilova S; Davi F; Hellström M; Jernberg-Wiklund H; Ghia P; Söderberg O; Stamatopoulos K; Nilsson M; Rosenquist R
J Exp Med; 2015 Jun; 212(6):833-43. PubMed ID: 25987724
[TBL] [Abstract][Full Text] [Related]
4. Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.
Della-Valle V; Roos-Weil D; Scourzic L; Mouly E; Aid Z; Darwiche W; Lecluse Y; Damm F; Mémet S; Mercher T; Aoufouchi S; Nguyen-Khac F; Bernard OA; Ghamlouch H
Blood Cancer J; 2020 Mar; 10(3):38. PubMed ID: 32170099
[TBL] [Abstract][Full Text] [Related]
5. NF-κB activation in chronic lymphocytic leukemia: A point of convergence of external triggers and intrinsic lesions.
Mansouri L; Papakonstantinou N; Ntoufa S; Stamatopoulos K; Rosenquist R
Semin Cancer Biol; 2016 Aug; 39():40-8. PubMed ID: 27491692
[TBL] [Abstract][Full Text] [Related]
6. Ibrutinib for improved chimeric antigen receptor T-cell production for chronic lymphocytic leukemia patients.
Fan F; Yoo HJ; Stock S; Wang L; Liu Y; Schubert ML; Wang S; Neuber B; Hückelhoven-Krauss A; Gern U; Schmitt A; Müller-Tidow C; Dreger P; Schmitt M; Sellner L
Int J Cancer; 2021 Jan; 148(2):419-428. PubMed ID: 32683672
[TBL] [Abstract][Full Text] [Related]
7. Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.
Mansouri L; Noerenberg D; Young E; Mylonas E; Abdulla M; Frick M; Asmar F; Ljungström V; Schneider M; Yoshida K; Skaftason A; Pandzic T; Gonzalez B; Tasidou A; Waldhueter N; Rivas-Delgado A; Angelopoulou M; Ziepert M; Arends CM; Couronné L; Lenze D; Baldus CD; Bastard C; Okosun J; Fitzgibbon J; Dörken B; Drexler HG; Roos-Weil D; Schmitt CA; Munch-Petersen HD; Zenz T; Hansmann ML; Strefford JC; Enblad G; Bernard OA; Ralfkiaer E; Erlanson M; Korkolopoulou P; Hultdin M; Papadaki T; Grønbæk K; Lopez-Guillermo A; Ogawa S; Küppers R; Stamatopoulos K; Stavroyianni N; Kanellis G; Rosenwald A; Campo E; Amini RM; Ott G; Vassilakopoulos TP; Hummel M; Rosenquist R; Damm F
Blood; 2016 Dec; 128(23):2666-2670. PubMed ID: 27670424
[TBL] [Abstract][Full Text] [Related]
8. Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice.
Hanna BS; Yazdanparast H; Demerdash Y; Roessner PM; Schulz R; Lichter P; Stilgenbauer S; Seiffert M
Haematologica; 2021 Apr; 106(4):968-977. PubMed ID: 32139435
[TBL] [Abstract][Full Text] [Related]
9. Microenvironmental stromal cells abrogate NF-κB inhibitor-induced apoptosis in chronic lymphocytic leukemia.
Simon-Gabriel CP; Foerster K; Saleem S; Bleckmann D; Benkisser-Petersen M; Thornton N; Umezawa K; Decker S; Burger M; Veelken H; Claus R; Dierks C; Duyster J; Zirlik K
Haematologica; 2018 Jan; 103(1):136-147. PubMed ID: 29122993
[TBL] [Abstract][Full Text] [Related]
10. Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation.
Kanagal-Shamanna R; Jain P; Patel KP; Routbort M; Bueso-Ramos C; Alhalouli T; Khoury JD; Luthra R; Ferrajoli A; Keating M; Jain N; Burger J; Estrov Z; Wierda W; Kantarjian HM; Medeiros LJ
Cancer; 2019 Feb; 125(4):559-574. PubMed ID: 30508305
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib modulates the immunosuppressive CLL microenvironment through STAT3-mediated suppression of regulatory B-cell function and inhibition of the PD-1/PD-L1 pathway.
Kondo K; Shaim H; Thompson PA; Burger JA; Keating M; Estrov Z; Harris D; Kim E; Ferrajoli A; Daher M; Basar R; Muftuoglu M; Imahashi N; Alsuliman A; Sobieski C; Gokdemir E; Wierda W; Jain N; Liu E; Shpall EJ; Rezvani K
Leukemia; 2018 Apr; 32(4):960-970. PubMed ID: 28972595
[TBL] [Abstract][Full Text] [Related]
12. Dissection of subclonal evolution by temporal mutation profiling in chronic lymphocytic leukemia patients treated with ibrutinib.
Gángó A; Alpár D; Galik B; Marosvári D; Kiss R; Fésüs V; Aczél D; Eyüpoglu E; Nagy N; Nagy Á; Krizsán S; Reiniger L; Farkas P; Kozma A; Ádám E; Tasnády S; Réti M; Matolcsy A; Gyenesei A; Mátrai Z; Bödör C
Int J Cancer; 2020 Jan; 146(1):85-93. PubMed ID: 31180577
[TBL] [Abstract][Full Text] [Related]
13. Disruption of in vivo Chronic Lymphocytic Leukemia Tumor-Microenvironment Interactions by Ibrutinib--Findings from an Investigator-Initiated Phase II Study.
Niemann CU; Herman SE; Maric I; Gomez-Rodriguez J; Biancotto A; Chang BY; Martyr S; Stetler-Stevenson M; Yuan CM; Calvo KR; Braylan RC; Valdez J; Lee YS; Wong DH; Jones J; Sun C; Marti GE; Farooqui MZ; Wiestner A
Clin Cancer Res; 2016 Apr; 22(7):1572-82. PubMed ID: 26660519
[TBL] [Abstract][Full Text] [Related]
14. BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinib.
Bonfiglio S; Sutton LA; Ljungström V; Capasso A; Pandzic T; Weström S; Foroughi-Asl H; Skaftason A; Gellerbring A; Lyander A; Gandini F; Gaidano G; Trentin L; Bonello L; Reda G; Bödör C; Stavroyianni N; Tam CS; Marasca R; Forconi F; Panayiotidis P; Ringshausen I; Jaksic O; Frustaci AM; Iyengar S; Coscia M; Mulligan SP; Ysebaert L; Strugov V; Pavlovsky C; Walewska R; Österborg A; Cortese D; Ranghetti P; Baliakas P; Stamatopoulos K; Scarfò L; Rosenquist R; Ghia P
Blood Adv; 2023 Jun; 7(12):2794-2806. PubMed ID: 36696464
[TBL] [Abstract][Full Text] [Related]
15. T Cells in Chronic Lymphocytic Leukemia: A Two-Edged Sword.
Vlachonikola E; Stamatopoulos K; Chatzidimitriou A
Front Immunol; 2020; 11():612244. PubMed ID: 33552073
[TBL] [Abstract][Full Text] [Related]
16. Cell-Intrinsic Determinants of Ibrutinib-Induced Apoptosis in Chronic Lymphocytic Leukemia.
Amin NA; Balasubramanian S; Saiya-Cork K; Shedden K; Hu N; Malek SN
Clin Cancer Res; 2017 Feb; 23(4):1049-1059. PubMed ID: 27535981
[No Abstract] [Full Text] [Related]
17. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
18. Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis.
Böttcher M; Bruns H; Völkl S; Lu J; Chartomatsidou E; Papakonstantinou N; Mentz K; Büttner-Herold M; Zenz T; Herling M; Huber W; Ghia P; Stamatopoulos K; Mackensen A; Mougiakakos D
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33931470
[TBL] [Abstract][Full Text] [Related]
19. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
20. NF-kB and the CLL microenvironment.
O'Donnell A; Pepper C; Mitchell S; Pepper A
Front Oncol; 2023; 13():1169397. PubMed ID: 37064123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
